Literature DB >> 22772070

Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation.

Brian Kornblit1, Yun Chen, Brenda M Sandmaier.   

Abstract

With the introduction of nonmyeloablative conditioning, hematopoietic cell transplantation (HCT) has become a viable treatment option for patients who due to age or comorbidities are ineligible for high dose conditioning. However, relapse and toxicities are still major problems in HCT. Radioimmunotherapy (RIT)-based conditioning is a promising approach that has the ability to specifically target radiation to hematopoietic cells. The most widely investigated isotopes are the β-emitters, but because of long path lengths and low linear energy transfer, α-emitters which have more favorable physical characteristics, might prove to be a better alternative. In the current study we have investigated the efficacy and safety of α-emitter based RIT as the only form of conditioning in a preclinical model of canine allogeneic HCT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772070      PMCID: PMC3442811          DOI: 10.4161/chim.20726

Source DB:  PubMed          Journal:  Chimerism        ISSN: 1938-1964


  26 in total

1.  Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.

Authors:  Wolfgang A Bethge; D Scott Wilbur; Rainer Storb; Donald K Hamlin; Erlinda B Santos; Martin W Brechbiel; Brenda M Sandmaier
Journal:  Transplantation       Date:  2004-08-15       Impact factor: 4.939

Review 2.  Radiovirotherapy: principles and prospects in oncology.

Authors:  Y Touchefeu; P Franken; K J Harrington
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Authors:  P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

4.  Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras.

Authors:  Christian S Kuhr; Margaret D Allen; Christian Junghanss; Jan M Zaucha; Christopher L Marsh; Murad Yunusov; Eustacia Zellme; Marie-Térèse Little; Beverly Torok-Storb; Rainer Storb
Journal:  Transplantation       Date:  2002-05-15       Impact factor: 4.939

5.  Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.

Authors:  Brenda M Sandmaier; Wolfgang A Bethge; D Scott Wilbur; Donald K Hamlin; Erlinda B Santos; Martin W Brechbiel; Darrell R Fisher; Rainer Storb
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

6.  Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.

Authors:  T Petrich; H-J Helmeke; G J Meyer; W H Knapp; E Pötter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-04-11       Impact factor: 9.236

7.  Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia.

Authors:  T L Andres; M E Kadin
Journal:  Am J Clin Pathol       Date:  1983-05       Impact factor: 2.493

8.  Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow.

Authors:  H Nakamura; R E Gress
Journal:  Transplantation       Date:  1990-02       Impact factor: 4.939

9.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.

Authors:  Dietger Niederwieser; Michael Maris; Judith A Shizuru; Effie Petersdorf; Ute Hegenbart; Brenda M Sandmaier; David G Maloney; Barry Storer; Thoralf Lange; Thomas Chauncey; Michael Deininger; Wolfram Pönisch; Claudio Anasetti; Ann Woolfrey; Marie-Terese Little; Karl G Blume; Peter A McSweeney; Rainer F Storb
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  Human homologue of murine T200 glycoprotein.

Authors:  M B Omary; I S Trowbridge; H A Battifora
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  2 in total

1.  Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Authors:  Raya Mawad; Ted A Gooley; Joseph G Rajendran; Darrell R Fisher; Ajay K Gopal; Andrew T Shields; Brenda M Sandmaier; Mohamed L Sorror; Hans Joachim Deeg; Rainer Storb; Damian J Green; David G Maloney; Frederick R Appelbaum; Oliver W Press; John M Pagel
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-20       Impact factor: 5.742

Review 2.  Genetic therapies for the first molecular disease.

Authors:  Phillip A Doerfler; Akshay Sharma; Jerlym S Porter; Yan Zheng; John F Tisdale; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.